Tanya Coleman - Concepedia

Concepedia

Author

Tanya Coleman

AstraZeneca (United Kingdom)

Also Known As

Coleman, T, T Coleman, T. Coleman, Tanya Coleman

46

Publications

1.3K

Citations

17

H-Index

38

Concepts

All Affiliations

AstraZeneca (United Kingdom)GlaxoSmithKline (United Kingdom)Newcastle University University of Surrey Molecular Discovery (United Kingdom)

TC

About

Tanya Coleman is an author at AstraZeneca (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	954
2	Biochemistry	11	11	323
3	Natural Sciences	6	6	161
4	Cell Biology	4	4	594
5	Health Sciences	1	1	47

Tanya Coleman

×

23

Publications

1.3K

Citations

17

H-Index

	Year	Citations
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family Paul R. Gavine, Lorraine Mooney, Elaine Kilgour, Cancer Research Fgfr SelectivityKinase InhibitorsPharmacotherapyTumor BiologySignaling Pathway	2012	491
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. Tanya Coleman, S. W. Ellis, Ian Martin, Journal of Pharmacology and Experimental Therapeutics	1996	96
Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84) Iain S. Haslam, Karen L. Jones, Tanya Coleman, Biochemical Pharmacology P-glycoprotein ExpressionMolecular PhysiologySignal TransductionMucosal ImmunologyCell Signaling	2008	68
Intestinal Ciprofloxacin Efflux: The Role of Breast Cancer Resistance Protein (ABCG2) Iain S. Haslam, Jayne Wright, Derek O’Reilly, Drug Metabolism and Disposition	2011	63
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes Katharine Howe, Faizah Sanat, Alfred E. Thumser, Xenobiotica	2011	61
Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue Iain S. Haslam, Derek O’Reilly, David Sherlock, Biopharmaceutics & Drug Disposition	2011	58
Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines Catherine Bardelle, Tanya Coleman, Darren A.E. Cross, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryDrug TargetBiochemistryNatural Sciences	2008	53
The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain Gerard M.P. Giblin, Rino A. Bit, Susan H. Brown, Bioorganic & Medicinal Chemistry Letters InflammationMedicinal ChemistryAnti-inflammatoryHealth SciencesBiochemistry	2006	47
Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells Iain S. Haslam, Karen L. Jones, Tanya Coleman, British Journal of Pharmacology	2008	46
Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1 Susan M. Westaway, Mervyn Thompson, Harshad K. Rami, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryDerivative (Chemistry)BiochemistryMedicine	2008	42

Page 1